Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.50 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31300137 | 0.90 | ROCK2 (0.66) | MDM2KDM4EMEN1KMT2AKEAP1 | |
| SCHEMBL12989329 | 0.82 | KMT2A (0.64) | MDM2KDM4EMEN1KMT2AKEAP1 | |
| SCHEMBL2236638 | 0.81 | EPHX1 (0.62) | KDM4EMEN1KMT2AHTTRAB9A | |
| SCHEMBL18436112 | 0.81 | MDM2 (0.60) | MDM2KDM4EMEN1KMT2AKEAP1 | |
| SCHEMBL9868290 | 0.81 | BCHE (0.62) | MDM2KDM4EMEN1KMT2AKEAP1 | |
| SCHEMBL3787099 | 0.80 | CDK2 (0.75) | KDM4EMEN1KMT2AKEAP1NFE2L2 | |
| SCHEMBL10939812 | 0.80 | CNR1 (0.70) | KDM4ERAB9A | |
| SCHEMBL6690096 | 0.80 | MAOA (0.53) | MEN1KMT2ARAB9A | |
| SCHEMBL11310806 | 0.79 | NAMPT (0.65) | MDM2KDM4EMEN1KMT2AKEAP1 | |
| SCHEMBL9600748 | 0.79 | SMARCA2 (0.63) | KDM4EMEN1KMT2AHTTSMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7501445-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-03-10 | — | — | US | disclosed |
| US-7501445-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-03-10 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| CN-1288148-C | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-06 | — | — | CN | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | VELKER JORG (DE) | 2004-12-02 | — | — | US | disclosed |
| US-6815451-B2 | 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-11-09 | — | — | US | disclosed |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-06-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-4329348-A | ANTIDEPRESSANTS AND PSYCHOSTIMULANTS | CIBA-GEIGY CORPORATION (US) | 1982-05-11 | — | — | US | disclosed |
| US-4075208-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | disclosed |
| US-4075335-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | disclosed |
| US-3956335-A | HYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | MDM2 629/4885KDM4E 3627/4885MEN1 203/4885 |
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | ADRA2C, ADRA1D, ADRB3 | MDM2 4244/4885KDM4E 2339/4885MEN1 396/4885 |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | UTS2R, NTSR2, NTSR1 | MDM2 4556/4885KDM4E 4223/4885MEN1 946/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | MDM2 629/4885KDM4E 3627/4885MEN1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.